Key result
Pre-procedural EASIX score ≥1.65 is linked to ~90% higher 3-year mortality after TAVR.
Why the study?
Endothelial dysfunction contributes to aortic stenosis progression, and the predictive value of the Endothelial Activation and Stress Index for long-term mortality in patients undergoing TAVR was unknown.
Does a pre-procedural EASIX ≥ 1.65 predict 3-year all-cause mortality in patients with severe aortic stenosis undergoing TAVR?
Cohort (n=1,084)
No
Does a pre-procedural EASIX ≥ 1.65 predict 3-year all-cause mortality in patients with severe aortic stenosis undergoing TAVR?
Hazard Ratio: 1.9 (95% CI 1.6–2.4)
Absolute Event Rate: 45.8% vs 27.7%
p-value: p=<0.001
Pre-procedural EASIX is an independent predictor of 3-year mortality in TAVR patients, but its predictive performance is inferior to established cardiac biomarkers like NT-proBNP and troponin T.
EASIX was associated with 3-year mortality after TAVR; leaves open added value beyond standard scores and requires prospective validation.
BACKGROUND: Endothelial dysfunction plays a crucial role in the progression of aortic stenosis (AS), and the Endothelial Activation and Stress Index (EASIX) has been proposed as a biomarker for predicting mortality in various clinical settings. AIMS: Evaluating the predictive value of the EASIX for 3-year all-cause mortality in patients undergoing transcatheter aortic valve replacement (TAVR). METHODS: We conducted a retrospective analysis of 1084 patients with severe AS, who underwent TAVR between 2013 and 2021 at the Heart Center Bonn. The EASIX was measured pre-procedural. The optimal cut-off (EASIX ≥ 1.65) was determined using the Youden index. Its association with 3-year mortality was assessed using Kaplan-Meier survival analysis and Cox regression models. The primary endpoint was 3-year all-cause mortality. RESULTS: Patients with an EASIX ≥ 1.65 had significantly higher 3-year mortality compared to those with lower EASIX (45.8% vs. 27.7%, p < 0.001). In multivariate analysis, EASIX remained an independent predictor of mortality (HR = 1.4, 95% CI: 1.1-1.8, p = 0.010). ROC analysis revealed an area under the curve (AUC) of 63.0% for the EASIX; its predictive ability was inferior to the well-established cardiac biomarkers such as NT-proBNP (AUC = 70.2%) and troponin T (AUC = 69.8%). CONCLUSION: The EASIX is a significant predictor of 3-year all-cause mortality in patients undergoing TAVR. However, its predictive performance is lower than NT-proBNP and troponin T. Integrating EASIX with traditional cardiac biomarkers may enhance risk stratification in TAVR patients and improve personalized care.
No takes yet. Share an insight, caveat, or question.
Basha et al. (2025) conducted a cohort in Severe aortic stenosis (n=1,084). EASIX ≥ 1.65 vs. EASIX < 1.65 was evaluated on 3-year all-cause mortality (HR 1.9, 95% CI 1.6-2.4, p=<0.001). A pre-procedural EASIX score ≥ 1.65 was associated with significantly higher 3-year all-cause mortality compared to lower scores (45.8% vs. 27.7%, HR 1.9) in patients undergoing TAVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: